✨ Free AI Report
Phio Pharmaceuticals Corp.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Phio Pharmaceuticals Corp.
Company Research

Phio Pharmaceuticals Corp.: Business Overview, Financials & Competitive Analysis

Phio Pharmaceuticals Corp. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Promising immuno-oncology platform with positive early clinical signals, but extreme capital constraints and clinical stage profile create significant execution risk. Early-stage asset with encouraging Phase 1b data showing 85% pathological response at highest dose; however, ultra-low market cap (~$11.6M), minimal cash runway, and high execution risk are significant concerns.

What is Phio Pharmaceuticals Corp.'s industry? Phio Pharmaceuticals Corp. (phiopharma.com) operates in Biopharmaceutical/Immuno-Oncology. AskCyborg classifies Phio Pharmaceuticals Corp. under Biopharmaceutical/Immuno-Oncology in its company registry.

Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary INTASYL self-delivering siRNA technology platform. The company is advancing PH-762, a...

5/ 10Mixed

Cyborg Score thesis

Promising immuno-oncology platform with positive early clinical signals, but extreme capital constraints and clinical stage...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Immuno-Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Phio Pharmaceuticals Corp. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Phio Pharmaceuticals Corp.

AskCyborg analysts argue the bull and bear cases for Phio Pharmaceuticals Corp. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Phio Pharmaceuticals Corp. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Phio Pharmaceuticals Corp. Overview

Pro stress-test →

Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary INTASYL self-delivering siRNA technology platform. The company is advancing PH-762, a lead candidate in Phase 1b trials for cutaneous squamous cell carcinoma and melanoma, with recent results showing promising safety and efficacy signals.

Strategic Profile

Pro stress-test →

Co-founded by Nobel Prize scientist Craig Mello (RNAi discoverer), Phio leverages advanced gene silencing technology to enhance immune cell effectiveness against tumor cells without requiring specialized drug delivery systems. The company is transitioning from discovery to development with recent leadership strengthening to support regulatory engagement and clinical advancement.

Competitive Landscape

Pro stress-test →

Phio competes in the immuno-oncology space against larger companies with established checkpoint inhibitors and cell therapies. Key differentiators include self-delivering siRNA technology avoiding complex formulations, and focus on underexplored targets (PD-1, BRD4) in skin cancers. Competitive positioning is early-stage with limited direct comparables; clinical validation and manufacturing scale-up are critical

Industry Context

Phio Pharmaceuticals Corp. operates in Biopharmaceutical/Immuno-Oncology.

Key facts

Founded: 2011 · Headquarters: Marlborough, Massachusetts, US · Employees: Unknown · Revenue: N/A · Market cap: $11.6M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Phio Pharmaceuticals Corp..

  • Phase 1b PH-762 trial shows 85% pathological response in highest dose cohort with no dose-limiting toxicities—rare positive safety/efficacy signal for early-stage oncology
  • INTASYL self-delivering siRNA platform targets cancer immunosuppression without complex drug delivery, providing potential competitive advantage in crowded immuno-oncology space
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Phase 1b PH-762 dose-escalation trial results: 70% overall response rate in cutaneous SCC patients, 85% response in highest dose cohort with complete tumor clearance in 4 of 6 responders
  • December 2025Leadership restructuring with new CFO, regulatory VP, and program development VP to support upcoming clinical milestones
  • +1 moreTrack every material event for Phio Pharmaceuticals Corp. as it happens. Explore monitoring →
Get alerted when Phio Pharmaceuticals Corp. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Checkpoint InhibitorsEstablished immuno-oncology class with PD-1/PD-L1 therapies→Cell Therapy PlatformsAdvanced cellular immunotherapy approaches→Early-Stage siRNA OncologyAlternative RNAi and gene silencing technologies→

Compare Phio Pharmaceuticals Corp. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Phio Pharmaceuticals Corp. operates in Biopharmaceutical/Immuno-Oncology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Immuno-Oncology research →
NEW · MCP server

Ask your AI assistant about Phio Pharmaceuticals Corp.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Phio Pharmaceuticals Corp. and its top competitor on Cyborg Score”
“What did Phio Pharmaceuticals Corp. do this quarter?”
“Is Phio Pharmaceuticals Corp. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Phio Pharmaceuticals Corp. do?+
Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary INTASYL self-delivering siRNA technology platform. The company is advancing PH-762, a...
What is Phio Pharmaceuticals Corp.'s Cyborg Score?+
Phio Pharmaceuticals Corp. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Phio Pharmaceuticals Corp.'s main competitors?+
Named competitors include Checkpoint Inhibitors, Cell Therapy Platforms, Early-Stage siRNA Oncology. The full competitive landscape is in the AskCyborg report.
How can I get the full Phio Pharmaceuticals Corp. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Phio Pharmaceuticals Corp. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Phio Pharmaceuticals Corp. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score